The GVAX vaccine platform, tested in clinical trials, consists of irradiated allogenic cancer cell lines that overexpress the granulocyte macrophage‐colony stimulating factor (GM‐CSF), which activates APCs and controls cancer progression.[24] Prompted by this, several clinical trials for allogenic tumor vaccines derived from tumor cells that secrete GM‐CSF, IL‐2, IL‐7, interferon‐γ (IFN‐γ), CD40, and CD80 have been carried out for prevention and therapeutic effects.[25] Most recently, neoantigens have been conspicuous in studies on cancer vaccine individuation. This evidence concerns the gene CD40 and neoplasm.